US FDA extends Novo Nordisk hemophilia drug review over facility issues

• Denecimig is intended to treat adults and children with hemophilia A, a rare blood clotting disorder, with the application originally submitted in September 2025
• The manufacturing facility issues do not affect any of Novo's currently marketed medicines, and the company is actively addressing FDA requests
• Novo Nordisk stated the delay will not impact its 2026 financial forecast

Summary: Novo Nordisk Hemophilia Drug Review Extended by FDA

The U.S. Food and Drug Administration (FDA) has delayed its review of Novo Nordisk's experimental hemophilia A treatment, denecimig, due to ongoing remediation work at a manufacturing facility, the Danish pharmaceutical company announced on October 2.

Key Details:

Novo Nordisk originally submitted the denecimig application in September 2025, anticipating FDA approval in Q3 2026. The drug is designed to treat adults and children with hemophilia A—a rare blood clotting disorder—with or without inhibitors.

The FDA has not established a new timeline for its decision. However, the agency confirmed no concerns regarding the drug's safety or effectiveness based on clinical trial data, indicating the delay is purely manufacturing-related.

Company Response:

CEO Mike Doustdar stated that Novo Nordisk is actively addressing the FDA's requests and working closely with the agency. The company emphasized that the manufacturing site issues do not affect any currently marketed medicines.

Despite the review extension, Novo Nordisk maintains its target to launch denecimig in the U.S. during the first half of 2027, subject to regulatory approval.

Financial Impact:

The company confirmed the delay will not impact its 2026 financial forecast, providing reassurance to investors about near-term earnings expectations.

Market Implications:

The setback represents a temporary hurdle in Novo Nordisk's expansion into the rare disease treatment market. While the manufacturing issues could raise short-term concerns about operational oversight, the FDA's validation of the drug's clinical efficacy suggests eventual approval remains likely, albeit on a delayed timeline.